# Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

> **NCT03219320** · PHASE2 · COMPLETED · sponsor: **Aptinyx** · enrollment: 301 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** NYX-2925
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03219320
- **Lead sponsor:** Aptinyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-27
- **Primary completion:** 2018-11-02
- **Final completion:** 2018-11-02
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219320, "Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03219320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*